- Home
- YSG vs KLTOW Comparison
YSG vs KLTOW Comparison
Compare YSG & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSG
- KLTOW
- Stock Information
- Founded
- YSG 2016
- KLTOW N/A
- Country
- YSG China
- KLTOW United States
- Employees
- YSG N/A
- KLTOW 3
- Industry
- YSG Package Goods/Cosmetics
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YSG Consumer Discretionary
- KLTOW Health Care
- Exchange
- YSG Nasdaq
- KLTOW Nasdaq
- Market Cap
- YSG 889.0M
- KLTOW N/A
- IPO Year
- YSG 2020
- KLTOW 2022
- Fundamental
- Price
- YSG $9.56
- KLTOW $0.26
- Analyst Decision
- YSG
- KLTOW
- Analyst Count
- YSG 0
- KLTOW 0
- Target Price
- YSG N/A
- KLTOW N/A
- AVG Volume (30 Days)
- YSG 759.2K
- KLTOW N/A
- Earning Date
- YSG 08-19-2025
- KLTOW N/A
- Dividend Yield
- YSG N/A
- KLTOW N/A
- EPS Growth
- YSG N/A
- KLTOW N/A
- EPS
- YSG N/A
- KLTOW N/A
- Revenue
- YSG $475,930,821.00
- KLTOW N/A
- Revenue This Year
- YSG $17.93
- KLTOW N/A
- Revenue Next Year
- YSG $12.79
- KLTOW N/A
- P/E Ratio
- YSG N/A
- KLTOW N/A
- Revenue Growth
- YSG 0.90
- KLTOW N/A
- 52 Week Low
- YSG $3.01
- KLTOW N/A
- 52 Week High
- YSG $11.57
- KLTOW N/A
- Technical
- Relative Strength Index (RSI)
- YSG 58.84
- KLTOW N/A
- Support Level
- YSG $9.18
- KLTOW N/A
- Resistance Level
- YSG $9.96
- KLTOW N/A
- Average True Range (ATR)
- YSG 0.81
- KLTOW 0.00
- MACD
- YSG -0.22
- KLTOW 0.00
- Stochastic Oscillator
- YSG 21.29
- KLTOW 0.00
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.